Advanced Biomed Inc. (ADVB): Nasdaq/NYSE listing notice — Advanced Biomed receives Nasdaq bid price deficiency notice; has 180 days to regain compliance

Advanced Biomed Inc.

Nasdaq notified ADVB on July 18, 2025, of bid price below $1.00 for 32 consecutive business days.
Company has until Jan 14, 2026 to regain compliance; must close at $1.00+ for 10 consecutive days.
If not cured, ADVB may get an extra 180 days if it meets other Nasdaq initial listing standards.
Company may consider a reverse stock split or other options to remedy the deficiency.
Common stock continues trading under symbol ADVB on Nasdaq Capital Market with no immediate impact.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Advanced Biomed Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

July 18, 2025, Advanced Biomed Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 32 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade o

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Advanced Biomed Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-067328

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.